ArticleLasers in medical science2025
Efficacy and safety of excimer laser atherectomy plus drug-coated balloon for infrapopliteal occlusive disease: a retrospective analysis.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCritical limb ischemia (CLI) due to infrapopliteal artery disease is a major cause of limb loss, prompting a shift toward endovascular therapy. This study compares the efficacy and safety of excimer laser atherectomy (ELA) combined with drug-coated balloon (DCB) angioplasty versus percutaneous transluminal angioplasty (PTA) with DCB in treating infrapopliteal lesions.
methodsIn this retrospective analysis of 112 patients treated from 2019 to 2021, 59 received ELA + DCB and 53 underwent PTA + DCB. The primary endpoints were 1-year primary vessel patency and freedom from target lesion revascularization (FTLR). Secondary endpoints included changes in Rutherford classification, ankle-brachial index (ABI), and adverse events. Kaplan-Meier analysis and chi-square tests were employed.
resultsBaseline characteristics were comparable (p > 0.05). At 12 months, primary patency was 79.7% in the ELA + DCB group versus 60.6% in the PTA + DCB group (p = 0.018). At 12 months, FTLR was significantly higher in the ELA + DCB group (88.1% vs. 73.6%, p = 0.049); at 6 months, FTLR rates were 93.2% vs. 79.3% (p = 0.303) for the ELA + DCB and PTA + DCB groups, respectively. Moreover, 88.1% of patients in the ELA + DCB group achieved ≥ 1 Rutherford category improvement versus 71.7% in the PTA + DCB group (p = 0.029) by 12 months. ABI values were significantly higher in the ELA + DCB group at both 6 months (0.80 ± 0.10 vs. 0.71 ± 0.14, p < 0.001) and 12 months (0.69 ± 0.21 vs. 0.61 ± 0.21, p = 0.044).
conclusionELA + DCB angioplasty provides superior mid-term vessel patency and reduces reintervention compared with PTA + DCB, supporting its role as a promising, minimally invasive treatment for infrapopliteal disease in patients with advanced symptomatic infrapopliteal disease, including those with CLTI. These findings contribute robust evidence to the evolving literature, though larger, multicenter studies with extended follow-up are warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40481838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.